search
Back to results

A Study Evaluating the Efficacy and the Benefit of Integrated Personalized Diabetes Management (PDM) for Diabetic Patients. (PDMProValueDSP)

Primary Purpose

Type II Diabetes Mellitus

Status
Completed
Phase
Not Applicable
Locations
Germany
Study Type
Interventional
Intervention
Accu-Chek Smart Pix Software
Accu-Chek Smart Pix readout Device
Sponsored by
Hoffmann-La Roche
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Type II Diabetes Mellitus focused on measuring Diabetes

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • existence of a signed Informed Consent form (before any study procedure)
  • diagnosed Type 2 diabetes mellitus
  • age ≥18 years
  • insulin therapy for ≥6 months: BOT, SIT, CT or ICT
  • HbA1c ≥7.5% (≥ 58,47 mmol/mol respectively), blood withdrawal for measurement in the last 90 days before study visit 1 (patient's inclusion)
  • longer-term care (at least for the duration of the 12-month study participation) by the trial site
  • insured by the statutory health insurance (GKV) as a compulsory member or voluntarily insured member or as a family co-insured member
  • willing and able to participate in the study and to follow the study procedures, among other things sufficient command of the German language, spoken and written

Exclusion Criteria:

  • Treatment of diabetes with insulin pump (CSII)
  • Methodic and continuous with the use of particular software for processing of SMBG data - by the patient and at visits in the practice by the physician/diabetes educator - in the past 12 months before study participation.presence of terminal renal failure (eGFR < 15ml/min) / dialysis and/or a loss of sight (visual acuity ≤ 0,05 of the better eye)
  • Existing tumor illness (primary tumor/local recurrence/ metastases except Basal Cell Carcinoma) in the past 5 years before study participation newly diagnosed or treated acutely (hormone, chemo- or radiation therapy). Within a tumor free time of < 5 years Medical Affairs will decide about individual cases
  • permanent use of steroids in adrenal suppressant doses, of other immuno-modulatory drugs or chemotherapy
  • known alcohol and drug abuse and medication abuse
  • known metabolic disorders and/or disorders or therapies that could lead to or have led to wrong measured results (e.g. with the blood glucose measurement)
  • existing pregnancy, breast-feeding or plan to become pregnant during study participation
  • physical illness and/or psychological disorder with the result that the patient cannot implement the medical treatment recommendations independently
  • dependency relationship to the sponsor or to the investigator, e.g. as a professional colleague or family member

Sites / Locations

  • Private Practice
  • Internistische Gemeinschaftspraxis
  • Forschungsinstitut der Diabetes Akademie Mergentheim (FIDAM)
  • Private Practice
  • Private Practice
  • MVZ am Bahnhof Spandau
  • Gemeinschaftspraxis
  • Private Practice
  • Private Practice
  • Diabetologicum Dresden
  • Universitätsklinikum Carl Gustav Carus
  • Gemeinschaftspraxis Schaden
  • Private Practice
  • Schwerpunktpraxis für Diabetes, Gefäß- und Ernährungsmedizin
  • Private Practice
  • Gemeinschaftspraxis
  • Private Practice
  • Hausärztliche internistische Gemeinschaftspraxis Giessen
  • Diabetes- und Gesundheitszentrum Göttingen
  • Private Practice
  • Private Practice
  • Diabeteszentrum
  • Private Practice
  • Integriertes Diabetiker-Zentrum Hannover
  • Gemeinschaftspraxis
  • Gemeinschaftspraxis im Altstadt-Carree
  • Private Practice
  • Universitätsklinikum Jena, Klinik für Innere Medizin III
  • Diabeteszentrum Kassel
  • Praxis Kugler
  • Internistische Praxis Lampertheim
  • Private Practice
  • Private Practice
  • Private Practice
  • Diabetes-Zentrum Neustadt
  • Diabetologische Schwerpunktpraxis
  • Private Practice
  • Diabetes Praxis Oranienburg
  • Arztpraxis fur Allg-Med
  • Private Practice
  • Private Practice
  • Gemeinschaftspraxis
  • Pivate Practice
  • Ambulanzzentrum Schweinfurt
  • Versdias Gmbh
  • Private Practice
  • Gemeinschaftspraxis am Bärenplatz
  • Diabetolog. Schwerpunktpraxis
  • Internistische Praxis
  • Arztpraxis Zossen / Dabendorf

Arms of the Study

Arm 1

Arm 2

Arm Type

Other

Other

Arm Label

Control Group

Intervention group

Arm Description

Patients treated by usual customary medical practice (Usual Care) in the out-patient facility i.e. Diabetes specialized medical practice, Medical Care Center or hospital outpatient clinic.

Patients are treated according to the concept "Integrated personalized diabetes management".

Outcomes

Primary Outcome Measures

The mean HbA1c change by means of Generalized Estimating Equations (GEE) methods
The difference in the HbA1c change after 12 months between the Intervention group and the Control group is analyzed by means of generalized estimating equations (Generalized Estimating Equations [GEE]) methods (population averaged model) and here, robust assessors (so-called sandwich assessors) for the standard errors are provided. The dependent variable is the HbA1c change after 12 months, while the HbA1c baseline considers the gender and the age as factors of influence (covariates) in the GEE model.

Secondary Outcome Measures

Effects of integrated Personalized Diabetes Management (PDM) by means of Generalized Estimating Equations [GEE] methods

Full Information

First Posted
June 3, 2014
Last Updated
November 13, 2017
Sponsor
Hoffmann-La Roche
Collaborators
Roche Diabetes Care Deutschland GmbH
search

1. Study Identification

Unique Protocol Identification Number
NCT02156349
Brief Title
A Study Evaluating the Efficacy and the Benefit of Integrated Personalized Diabetes Management (PDM) for Diabetic Patients.
Acronym
PDMProValueDSP
Official Title
Integrated Personalized Diabetes Management (Integrated PDM): Prospective, Randomized, Controlled Intervention Study for the Evaluation of the Effectiveness and the Benefit of Integrated PDM in the Care of People With Type 2 Diabetes in Diabetes Specialized Medical Practices in Germany (DSP)
Study Type
Interventional

2. Study Status

Record Verification Date
November 2017
Overall Recruitment Status
Completed
Study Start Date
May 14, 2014 (Actual)
Primary Completion Date
April 10, 2017 (Actual)
Study Completion Date
April 10, 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hoffmann-La Roche
Collaborators
Roche Diabetes Care Deutschland GmbH

4. Oversight

5. Study Description

Brief Summary
This study is a German, prospective, multicenter, controlled, cluster-randomized, interventional comparative study evaluating the efficacy and benefits of integrated PDM care by measuring HbA1c levels in patients with Type 2 Diabetes. Patients will be randomized into two groups to use Accu-Chek Smartpix software and Accu-Chek Smartpix device.
Detailed Description
Outcome of both studies (RD001732 and RD001231) will be integrated and additionally reported as PDM-ProValue study program (Integrated Personalized Diabetes Management) due to the high similarity in study characteristics, design and study results.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type II Diabetes Mellitus
Keywords
Diabetes

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
558 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Control Group
Arm Type
Other
Arm Description
Patients treated by usual customary medical practice (Usual Care) in the out-patient facility i.e. Diabetes specialized medical practice, Medical Care Center or hospital outpatient clinic.
Arm Title
Intervention group
Arm Type
Other
Arm Description
Patients are treated according to the concept "Integrated personalized diabetes management".
Intervention Type
Device
Intervention Name(s)
Accu-Chek Smart Pix Software
Intervention Description
Software with adherence evaluation software used according to Integrated Personalized Diabetes Management (PDM)
Intervention Type
Device
Intervention Name(s)
Accu-Chek Smart Pix readout Device
Intervention Description
Smartpix device for data upload out of blood glucose meter devices
Primary Outcome Measure Information:
Title
The mean HbA1c change by means of Generalized Estimating Equations (GEE) methods
Description
The difference in the HbA1c change after 12 months between the Intervention group and the Control group is analyzed by means of generalized estimating equations (Generalized Estimating Equations [GEE]) methods (population averaged model) and here, robust assessors (so-called sandwich assessors) for the standard errors are provided. The dependent variable is the HbA1c change after 12 months, while the HbA1c baseline considers the gender and the age as factors of influence (covariates) in the GEE model.
Time Frame
from Baseline to 12 months
Secondary Outcome Measure Information:
Title
Effects of integrated Personalized Diabetes Management (PDM) by means of Generalized Estimating Equations [GEE] methods
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: existence of a signed Informed Consent form (before any study procedure) diagnosed Type 2 diabetes mellitus age ≥18 years insulin therapy for ≥6 months: BOT, SIT, CT or ICT HbA1c ≥7.5% (≥ 58,47 mmol/mol respectively), blood withdrawal for measurement in the last 90 days before study visit 1 (patient's inclusion) longer-term care (at least for the duration of the 12-month study participation) by the trial site insured by the statutory health insurance (GKV) as a compulsory member or voluntarily insured member or as a family co-insured member willing and able to participate in the study and to follow the study procedures, among other things sufficient command of the German language, spoken and written Exclusion Criteria: Treatment of diabetes with insulin pump (CSII) Methodic and continuous with the use of particular software for processing of SMBG data - by the patient and at visits in the practice by the physician/diabetes educator - in the past 12 months before study participation.presence of terminal renal failure (eGFR < 15ml/min) / dialysis and/or a loss of sight (visual acuity ≤ 0,05 of the better eye) Existing tumor illness (primary tumor/local recurrence/ metastases except Basal Cell Carcinoma) in the past 5 years before study participation newly diagnosed or treated acutely (hormone, chemo- or radiation therapy). Within a tumor free time of < 5 years Medical Affairs will decide about individual cases permanent use of steroids in adrenal suppressant doses, of other immuno-modulatory drugs or chemotherapy known alcohol and drug abuse and medication abuse known metabolic disorders and/or disorders or therapies that could lead to or have led to wrong measured results (e.g. with the blood glucose measurement) existing pregnancy, breast-feeding or plan to become pregnant during study participation physical illness and/or psychological disorder with the result that the patient cannot implement the medical treatment recommendations independently dependency relationship to the sponsor or to the investigator, e.g. as a professional colleague or family member
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Iris Vesper
Organizational Affiliation
Roche Diabetes Care Deutschland GmbH
Official's Role
Study Director
Facility Information:
Facility Name
Private Practice
City
Altenstadt
ZIP/Postal Code
63674
Country
Germany
Facility Name
Internistische Gemeinschaftspraxis
City
Augsburg
ZIP/Postal Code
86179
Country
Germany
Facility Name
Forschungsinstitut der Diabetes Akademie Mergentheim (FIDAM)
City
Bad Mergentheim
ZIP/Postal Code
97980
Country
Germany
Facility Name
Private Practice
City
Bad Sackingen
ZIP/Postal Code
79713
Country
Germany
Facility Name
Private Practice
City
Berlin
ZIP/Postal Code
01627
Country
Germany
Facility Name
MVZ am Bahnhof Spandau
City
Berlin
ZIP/Postal Code
13597
Country
Germany
Facility Name
Gemeinschaftspraxis
City
Bitburg
ZIP/Postal Code
54634
Country
Germany
Facility Name
Private Practice
City
Buxtehude
ZIP/Postal Code
21614
Country
Germany
Facility Name
Private Practice
City
Cuxhaven
ZIP/Postal Code
27474
Country
Germany
Facility Name
Diabetologicum Dresden
City
Dresden
ZIP/Postal Code
01219
Country
Germany
Facility Name
Universitätsklinikum Carl Gustav Carus
City
Dresden
ZIP/Postal Code
01307
Country
Germany
Facility Name
Gemeinschaftspraxis Schaden
City
Dusseldorf
ZIP/Postal Code
40212
Country
Germany
Facility Name
Private Practice
City
Essen
ZIP/Postal Code
45329
Country
Germany
Facility Name
Schwerpunktpraxis für Diabetes, Gefäß- und Ernährungsmedizin
City
Falkensee
ZIP/Postal Code
14612
Country
Germany
Facility Name
Private Practice
City
Frankfurt am Main
ZIP/Postal Code
60326
Country
Germany
Facility Name
Gemeinschaftspraxis
City
Fulda
ZIP/Postal Code
36039
Country
Germany
Facility Name
Private Practice
City
Gelnhausen
ZIP/Postal Code
63571
Country
Germany
Facility Name
Hausärztliche internistische Gemeinschaftspraxis Giessen
City
Giessen
ZIP/Postal Code
35390
Country
Germany
Facility Name
Diabetes- und Gesundheitszentrum Göttingen
City
Gottingen
ZIP/Postal Code
37073
Country
Germany
Facility Name
Private Practice
City
Gummersbach
ZIP/Postal Code
51645
Country
Germany
Facility Name
Private Practice
City
Hamburg
ZIP/Postal Code
21109
Country
Germany
Facility Name
Diabeteszentrum
City
Hamburg
ZIP/Postal Code
22119
Country
Germany
Facility Name
Private Practice
City
Hanau
ZIP/Postal Code
63450
Country
Germany
Facility Name
Integriertes Diabetiker-Zentrum Hannover
City
Hannover
ZIP/Postal Code
30159
Country
Germany
Facility Name
Gemeinschaftspraxis
City
Herne
ZIP/Postal Code
44653
Country
Germany
Facility Name
Gemeinschaftspraxis im Altstadt-Carree
City
Hessen
ZIP/Postal Code
36037
Country
Germany
Facility Name
Private Practice
City
Immenhausen
ZIP/Postal Code
34376
Country
Germany
Facility Name
Universitätsklinikum Jena, Klinik für Innere Medizin III
City
Jena
ZIP/Postal Code
07743
Country
Germany
Facility Name
Diabeteszentrum Kassel
City
Kassel
ZIP/Postal Code
34117
Country
Germany
Facility Name
Praxis Kugler
City
Koln
ZIP/Postal Code
50858
Country
Germany
Facility Name
Internistische Praxis Lampertheim
City
Lampertheim
ZIP/Postal Code
68623
Country
Germany
Facility Name
Private Practice
City
Lauf (Pegnitz)
ZIP/Postal Code
91207
Country
Germany
Facility Name
Private Practice
City
Laupheim
ZIP/Postal Code
88471
Country
Germany
Facility Name
Private Practice
City
Lingen
ZIP/Postal Code
49808
Country
Germany
Facility Name
Diabetes-Zentrum Neustadt
City
Neustadt am Rübenberge
ZIP/Postal Code
31535
Country
Germany
Facility Name
Diabetologische Schwerpunktpraxis
City
Nordrhein-Westfalen
ZIP/Postal Code
46537
Country
Germany
Facility Name
Private Practice
City
Offenbach
ZIP/Postal Code
63065
Country
Germany
Facility Name
Diabetes Praxis Oranienburg
City
Oranienburg
ZIP/Postal Code
16515
Country
Germany
Facility Name
Arztpraxis fur Allg-Med
City
Pirna
ZIP/Postal Code
01796
Country
Germany
Facility Name
Private Practice
City
Porta Westfalica
ZIP/Postal Code
32457
Country
Germany
Facility Name
Private Practice
City
Rehburg-Loccum
ZIP/Postal Code
31547
Country
Germany
Facility Name
Gemeinschaftspraxis
City
Rhaunen
ZIP/Postal Code
55624
Country
Germany
Facility Name
Pivate Practice
City
Russelsheim
ZIP/Postal Code
65428
Country
Germany
Facility Name
Ambulanzzentrum Schweinfurt
City
Schweinfurt
ZIP/Postal Code
97421
Country
Germany
Facility Name
Versdias Gmbh
City
Sulzbach-Rosenberg
ZIP/Postal Code
92237
Country
Germany
Facility Name
Private Practice
City
Trier
ZIP/Postal Code
54292
Country
Germany
Facility Name
Gemeinschaftspraxis am Bärenplatz
City
Villingen-Schwenningen
ZIP/Postal Code
78054
Country
Germany
Facility Name
Diabetolog. Schwerpunktpraxis
City
Wiesbaden
ZIP/Postal Code
65183
Country
Germany
Facility Name
Internistische Praxis
City
Zierenberg
ZIP/Postal Code
34289
Country
Germany
Facility Name
Arztpraxis Zossen / Dabendorf
City
Zossen
ZIP/Postal Code
15806
Country
Germany

12. IPD Sharing Statement

Learn more about this trial

A Study Evaluating the Efficacy and the Benefit of Integrated Personalized Diabetes Management (PDM) for Diabetic Patients.

We'll reach out to this number within 24 hrs